Skip to main content
. Author manuscript; available in PMC: 2015 May 15.
Published in final edited form as: J Nucl Med. 2010 Jan;51(1):121–129. doi: 10.2967/jnumed.109.066126

FIGURE 3.

FIGURE 3

Direct in vivo imaging of Abl expression in rat xenograft human CML model. (A) Time series of axial PET Advance images of rat, bearing tumor model K562 overexpressing BCR-Abl representing biodistribution of 124I-SKI230 in animal. (B) Sagittal projection of accumulation of 124I-SKI230 in Abl-expressing CML tumor model in shoulder area 90 min after administration of direct PKI imaging agent. (C) Pharmacokinetic profile of 124I-SKI230 biodistribution in organs and tissues quantified using image analysis of radiotracer accumulation based on ROI analysis of dynamic frames. (D) Ex vivo well counts calculated for tissue samples obtained by postmortem tissue collection (at 90 min) confirming SKI230 pharmacokinetic results.